Clinical Trial Update: Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab with anlotinib for perioperative non-small cell lung cancer guided by minimal residual disease assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Non-small Cell Lung Cancer, Minimal Residual Disease | Phase 2 | Status: UNKNOWN